MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- VENUS REMEDIES - TEVA PHARMA (Israel)
VENUS REMEDIES vs TEVA PHARMA (Israel) - Comparison Results
TEVA PHARMA (Israel)
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
Financials
 VENUS REMEDIES  TEVA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| VENUS REMEDIES Mar-18 |
TEVA PHARMA Dec-13 |
VENUS REMEDIES/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 126 | 3,110 | - | |
| Low | Rs | 61 | 2,702 | - | |
| Sales per share (Unadj.) | Rs | 301.8 | 1,784.9 | - | |
| Earnings per share (Unadj.) | Rs | -24.9 | 111.5 | - | |
| Cash flow per share (Unadj.) | Rs | 2.5 | 255.8 | - | |
| Dividends per share (Unadj.) | Rs | 0 | 97.61 | - | |
| Dividend yield (eoy) | % | 0 | 3.4 | 0.0% | |
| Book value per share (Unadj.) | Rs | 293.3 | 1,982.7 | - | |
| Shares outstanding (eoy) | m | 12.34 | 848.00 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 0.3 | 1.6 | 19.0% | |
| Avg P/E ratio | x | -3.8 | 26.1 | -14.4% | |
| P/CF ratio (eoy) | x | 36.7 | 11.4 | 323.4% | |
| Price / Book Value ratio | x | 0.3 | 1.5 | 21.8% | |
| Dividend payout | % | 0 | 87.5 | 0.0% | |
| Avg Mkt Cap | Rs m | 1,154 | 2,464,195 | 0.0% | |
| No. of employees | `000 | 0.9 | 44.9 | 2.1% | |
| Total wages/salary | Rs m | 393 | 0 | - | |
| Avg. sales/employee | Rs Th | 4,026.1 | 33,676.6 | 12.0% | |
| Avg. wages/employee | Rs Th | 425.0 | 0 | - | |
| Avg. net profit/employee | Rs Th | -331.8 | 2,103.8 | -15.8% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 3,724 | 1,513,596 | 0.2% | |
| Other income | Rs m | 23 | 0 | - | |
| Total revenues | Rs m | 3,747 | 1,513,596 | 0.2% | |
| Gross profit | Rs m | 395 | 414,499 | 0.1% | |
| Depreciation | Rs m | 338 | 122,345 | 0.3% | |
| Interest | Rs m | 354 | 29,729 | 1.2% | |
| Profit before tax | Rs m | -275 | 262,424 | -0.1% | |
| Minority Interest | Rs m | 0 | 1,192 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -172,267 | 0.0% | |
| Tax | Rs m | 32 | -3,204 | -1.0% | |
| Profit after tax | Rs m | -307 | 94,553 | -0.3% | |
| Gross profit margin | % | 10.6 | 27.4 | 38.7% | |
| Effective tax rate | % | -11.5 | -1.2 | 940.2% | |
| Net profit margin | % | -8.2 | 6.2 | -131.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 2,638 | 1,022,277 | 0.3% | |
| Current liabilities | Rs m | 2,305 | 891,512 | 0.3% | |
| Net working cap to sales | % | 8.9 | 8.6 | 103.5% | |
| Current ratio | x | 1.1 | 1.1 | 99.8% | |
| Inventory Days | Days | 135 | 91 | 149.2% | |
| Debtors Days | Days | 46 | 96 | 48.3% | |
| Net fixed assets | Rs m | 4,871 | 494,374 | 1.0% | |
| Share capital | Rs m | 123 | 3,726 | 3.3% | |
| Net worth | Rs m | 3,619 | 1,681,318 | 0.2% | |
| Long term debt | Rs m | 1,374 | 773,935 | 0.2% | |
| Total assets | Rs m | 7,509 | 3,459,052 | 0.2% | |
| Interest coverage | x | 0.2 | 9.8 | 2.3% | |
| Debt to equity ratio | x | 0.4 | 0.5 | 82.5% | |
| Sales to assets ratio | x | 0.5 | 0.4 | 113.3% | |
| Return on assets | % | 0.6 | 3.6 | 17.6% | |
| Return on equity | % | -8.5 | 5.6 | -150.8% | |
| Return on capital | % | 1.6 | 4.9 | 32.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 514 | 241,189 | 0.2% | |
| From Investments | Rs m | -123 | -85,463 | 0.1% | |
| From Financial Activity | Rs m | -387 | -289,322 | 0.1% | |
| Net Cashflow | Rs m | 4 | -133,596 | -0.0% | |
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 74.51 Rs / USD
Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare VENUS REMEDIES With: NATCO PHARMA SANOFI INDIA DISHMAN PHARMA ABBOTT INDIA STRIDES PHARMA SCIENCE
Today's Market
6 Reasons Why Sensex Plunged 883 Points Today(Closing)
Indian share markets nosedived and registered sharp losses in today's volatile session following a strong second wave of Covid-19 in the country.
Related Views On News
VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)
Jun 12, 2019 | Updated on Jun 12, 2019For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)
Apr 6, 2021Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
A Unique Sector for Short-Term Profits (Fast Profits Daily)
Apr 12, 2021This ignored sector could deliver big short-term profits.
More
